Fortress Biotech Inc (OQ:FBIO)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 1111 KANE CONCOURSE, SUITE 301
BAY HARBOR ISLANDS FL 33154
Tel: 1-781-6524500
Website: https://www.fortressbiotech.com
IR: See website
<
Key People
Lindsay A. Rosenwald
Executive Chairman of the Board, President, Chief Executive Officer
Eric K. Rowinsky
Co-Vice Chairman of the Board
David Jin
Chief Financial Officer, Corporate Secretary
Michael S. Weiss
Executive Vice Chairman - Strategic Development, Director
George C. Avgerinos
Senior Vice President - Biologics Operations
 
Business Overview
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products and product candidates. The Company markets its various branded dermatology products, Qbrexza, Accutane, Amzeeq, Zilxi, Ximino, Exelderm and Targadox. Qbrexza (glycopyrronium 2.4%) is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis in adults and children nine years and older. Accutane (isotretinoin) is an oral capsule for the treatment of severe recalcitrant nodular acne. Amzeeq (minocycline 4%) topical foam is a topical minocycline treatment for the inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and children nine years and older. Zilxi (minocycline 1.5%) is a topical foam and a topical minocycline treatment for inflammatory lesions of rosacea in adults. Ximino (minocycline hydrochloride) is an oral minocycline drug for the treatment of moderate to severe acne.
Financial Overview
For the nine months ended 30 September 2023, Fortress Biotech Inc revenues increased 9% to $64.6M. Net loss applicable to common stockholders decreased 13% to $57.4M. Revenues reflect Dermatology Product segment increase of 11% to $63.9M. Lower net loss reflects General and administarative decrease of 15% to $60.5M (expense), Research and developement decrease of 11% to $85.3M (expense).
Employees: 187 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $16.36M as of Sep 30, 2023
Annual revenue (TTM): $80.97M as of Sep 30, 2023
EBITDA (TTM): -$167.18M as of Sep 30, 2023
Net annual income (TTM): -$84.33M as of Sep 30, 2023
Free cash flow (TTM): -$150.03M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 18,376,750 as of Jan 3, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.